The DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index; 33 of the 112 sources its claims cite were checked for support.
The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives
Open accessAbstract
Background/Objectives: Colorectal cancer (CRC) remains a leading cause of cancer mortality globally, with KRAS mutations occurring in 30–40% of cases, contributing to poor prognosis and resistance to anti-EGFR therapy. This review explores the biological significance, clinical implications, and therapeutic targeting of KRAS mutations in CRC. Methods: A comprehensive analysis of the existing literature and clinical trials was performed, highlighting the role of KRAS mutations in CRC pathogenesis, their impact on prognosis, and recent advancements in targeted therapies. Specific attention was given to emerging therapeutic strategies and resistance mechanisms. Results: KRAS mutations drive tumor progression through persistent activation of MAPK/ERK and PI3K/AKT signaling pathways. These mutations influence the tumor microenvironment, cancer stem cell formation, macropinocytosis, and cell competition. KRAS-mutant CRC exhibits poor responsiveness to anti-EGFR monoclonal antibodies and demonstrates primary and acquired resistance to KRAS inhibitors. Recent breakthroughs include the development of KRAS G12C inhibitors (sotorasib and adagrasib) and promising agents targeting G12D mutations. However, response rates in CRC remain suboptimal compared to other cancers, necessitating combination therapies and novel approaches, such as vaccines, nucleic acid-based therapeutics, and macropinocytosis inhibitors. Conclusions: KRAS mutations are central to CRC pathogenesis and present a significant therapeutic challenge. Advances in KRAS-targeted therapies offer hope for improved outcomes, but resistance mechanisms and organ-specific differences limit efficacy. Continued efforts in personalized treatment strategies and translational research are critical for overcoming these challenges and improving patient survival.
Overview
CoChat Summary
TL;DR
KRAS mutations occur in roughly 30–40% of colorectal cancers and drive MAPK/ERK and PI3K/AKT signaling, poor prognosis, and resistance to anti-EGFR antibodies. Although KRASG12C inhibitors such as sotorasib and adagrasib are breakthroughs, their efficacy in colorectal cancer remains limited, so combination therapies, G12D/G12X/SOS1 inhibitors, vaccines, peptides, and nucleic acid therapeutics are under development.
Key findings
- KRAS mutations are found in 30–40% of colorectal cancer cases and are associated with persistent activation of MAPK/ERK and PI3K/AKT pathways, poor prognosis, and resistance to anti-EGFR monoclonal antibodies such as panitumumab and cetuximab.
- In colorectal cancer, KRASG12C inhibitors have an overall response rate of only around 10%; KRASG12C mutations occur in only 3–4% of colorectal cancer cases, whereas G12D is found in 28% of colorectal cancers and 39% of pancreatic cancers.
- Sotorasib showed a 33.3% response rate, 57.9% stable disease rate, and 91.2% disease control rate in non-small cell lung cancer; adagrasib showed a 42.9% response rate. In KRASG12C-mutant colorectal cancer, combination KRASG12C plus EGFR inhibition produced a 43% response rate (12/28 patients) versus 22% (10/45 patients) with KRASG12C inhibitor monotherapy.
- RAS-mutant colorectal cancer patients continue to have poor outcomes, with overall survival remaining at 15–17 months despite advances in systemic therapy.
Methods
- This is a narrative review, not an original research study; it synthesizes prior biological, clinical, and therapeutic literature on KRAS-mutant colorectal cancer.
- No primary sample, dataset, or statistical analysis is reported; the paper draws on cited clinical trials, preclinical studies, and mechanistic reports.
- The review covers KRAS biology, clinical testing, resistance mechanisms, and emerging therapeutic strategies including small-molecule inhibitors, peptides, vaccines, metabolic targeting, and oligonucleotide therapeutics.
Limitations
- Stated in the paper: RAS mutation testing cannot achieve 100% accuracy because of testing method sensitivity, sample quality, and tumor cell content; there are no guidelines defining the threshold level of mutant RAS that impacts treatment efficacy, and it remains unclear which RAS mutant types have the highest clinical utility.
- Stated in the paper: resistance to KRAS-targeted therapy is common, with primary and acquired resistance mechanisms including feedback pathway activation, KRAS independence, organ-specific sensitivity, EMT, secondary mutations, and bypass signaling.
- Evident from the text: as a narrative review, it does not describe a systematic search strategy, risk-of-bias assessment, or meta-analysis, and it presents no original patient-level data.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
20 Valid · 4 Not valid · 55 Not checked · 28 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“pulmonary metastases have shown a markedly higher discordance rate (approximately 30%) compared to other sites [54,55]”
§ The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives > 5. Challenges and Limitations of Current Treatment > 5.2. Challenges in the Interpretation of RAS Mutations
What the sources say
- Disputedcites [54] Santini, 2008, High concordance of KRAS status between primary colorectal tumors and related metastatic sites: Implications for clinical practice, Oncologist sourceExperimental — accuracy not yet measured
The Results report seven lung metastases, but none of the four discordant cases involved the lung: three involved the liver and one the peritoneum. The reported pulmonary discordance rate in this sample was therefore 0%, not approximately 30% or higher than at other sites. (LLM, conf=0.92)
Checked by a reasoning model — may be wrong.
- Not checked yetcites [55] Italiano, 2010, KRAS and BRAF mutational status in primary colorectal tumors and related metastatic sites: Biological and clinical implications, Ann. Surg. Oncol. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“discordance in KRAS mutation status is rare in distant organ metastases (less than 10%) [52,53]”
§ The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives > 5. Challenges and Limitations of Current Treatment > 5.2. Challenges in the Interpretation of RAS Mutations
What the sources say
- Not checked yetcites [52] Watanabe, 2011, Heterogeneity of KRAS status may explain the subset of discordant KRAS status between primary and metastatic colorectal cancer, Dis. Colon. Rectum source
- Partly supportedcites [53] Knijn, 2011, KRAS mutation analysis: A comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients, Br. J. Cancer sourceExperimental — accuracy not yet measured
The Results section ('Concordance of KRAS status in primary tumours and corresponding liver metastases') reports 96.4% concordance (3.6% discordance, 11/305; clinically relevant in only 2.0%), and the Abstract Conclusion repeats this, so the '<10%' magnitude is supported — but strictly for liver metastases. The claim generalises to 'distant organ metastases', which the source explicitly refuses: the Discussion states 'The results of our study are only valid for liver metastases and cannot be extrapolated to other metastatic locations', and notes molecular patterns may differ between metastatic sites (Klein, 2009). The same Discussion also reports 25% discordance for lymph node metastases, concluding they are unsuitable for KRAS testing, further limiting the generalisation. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Found in 30–40% of cases”
- Also stated in: § 4. Clinical Significance of KRAS Mutations (Role in Practice and Therapeutics) · hedged
“Approximately 30–40% of colorectal cancer cases harbor KRAS mutations”
§ The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives > Abstract
What the sources say
- Not checked yetcites [45] Watanabe, 2013, KRAS mutational status in Japanese patients with colorectal cancer: Results from a nationwide, multicenter, cross-sectional study, Jpn. J. Clin. Oncol. source
- Supportedcites [46] Andreyev, 1998, Kirsten ras mutations in patients with colorectal cancer: The multicenter “RASCAL” study, J. Natl. Cancer Inst. source
The RASCAL study's headline prevalence is 37.7% for Ki-ras codon 12/13 mutations, stated in the abstract Results and in the section 'Status of the Ki-ras Gene at Codons 12 and 13 (Table 3)' (835 of 2214 patients, based on 2721 patients from 22 groups in 13 countries). Subgroup rates in 'Ki-ras and Histology (Table 4)' span 30.7% (poorly differentiated) to 41.3% (moderately differentiated) and 33.9-39.8% across Dukes' stages, and predisposing-condition groups in 'Ki-ras and Predisposing Causes' run 30.6-34.5%, all consistent with a 30-40% band. The paper reports a point estimate rather than the range verbatim, but the cited prevalence falls squarely within what our copy states for colorectal cancer cases. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 4. Clinical Significance of KRAS Mutations (Role in Practice and Therapeutics) · hedged
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“the efficacy of RAS inhibitors remains low in colorectal cancer, with an overall response rate of only around 10% [44]”
§ The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives > 4. Clinical Significance of KRAS Mutations (Role in Practice and Therapeutics)
What the sources say
- Partly supportedcites [44] Akhave, 2021, Mechanisms of Resistance to KRAS(G12C)-Targeted Therapy, Cancer Discov. sourceExperimental — accuracy not yet measured
The “Proof of therapeutic targeting of KRASG12C” section reports colorectal cancer overall response rates of 7.1% for sotorasib and 17% in preliminary adagrasib results, consistent with a low response rate around 10%. These figures concern KRASG12C inhibitors in patients with advanced, previously treated disease; they do not establish that rate for RAS inhibitors generally or for all colorectal cancer. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Adagrasib also showed promising results with a response rate of 42.9% [44]”
§ The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives > 4. Clinical Significance of KRAS Mutations (Role in Practice and Therapeutics)
What the sources say
- Partly supportedcites [44] Akhave, 2021, Mechanisms of Resistance to KRAS(G12C)-Targeted Therapy, Cancer Discov. sourceExperimental — accuracy not yet measured
Our copy supports that adagrasib showed promising activity in KRASG12C NSCLC, but the magnitude it reports differs: the 'Proof of therapeutic targeting of KRASG12C' section gives ORR and DCR of 45% and 96% in NSCLC (and 17% and 96% in CRC) from preliminary results presented at the EORTC-NCI-AACR Annual Symposium 2020 for the ongoing Phase I/II trial NCT03785249, while the Introduction summarizes both agents' early-phase tumor response rates as 'approximating 30–40%'. The specific figure of 42.9% attributed to this source appears nowhere in our copy (searched: 42.9%, adagrasib overall response rate NSCLC, Table 1 agent summary), so the qualitative claim holds but the numeric value does not. Our copy also frames that adagrasib number as preliminary conference data, with no complete responses and responses lasting only 4–6 months, which the citing sentence omits. (LLM, conf=0.75)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
57 more claims · 14 with their cited sources checked
Create a free account to see all 107 claims and to verify the 79 references still open.
- It may state two separate claims as one. 41
- Probably not a substantial claim. 9
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Mutations in RAS, importantly, the KRAS-mutated tumors, are associated with around forty percent of CRCs [12,18,19], while NRAS is less frequent but remains a clinically relevant contributor to tumor heterogeneity.”
From Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies (2026) · cites this paper as [12]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives > 5. Challenges and Limitations of Current Treatment > 5.3. Resistance in RAS-Targeted Therapy
“the response rate of KRASG12C inhibitors in colorectal cancer is approximately 40%”
§ The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives > 5. Challenges and Limitations of Current Treatment > 5.3. Resistance in RAS-Targeted Therapy
“the response rate in lung cancer is approximately 40%, whereas in colorectal cancer, it is around 10–20%”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives > 4. Clinical Significance of KRAS Mutations (Role in Practice and Therapeutics)
“KRASG12C mutations are present in only 3–4% of colorectal cancer cases”
§ The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives > 6. Future Strategies and Perspectives > 6.2. Development of Targeted Therapies for Mutations Beyond KRASG12C
“this mutation is relatively rare in gastrointestinal cancers, occurring in only 7% of colorectal cancers and 1% of pancreatic cancers”
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Tournigand, C., André, T., Achille, E., Lledo, G., Flesh, M., Mery-Mignard, D., Quinaux, E., Couteau, C., Buyse, M., Ganem, G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.113 · Cited by 2,915 · cited 1×
“However, with treatments such as FOLFOX or FOLFIRI, which combine 5-FU, oxaliplatin, and irinotecan, survival has been extended to approximately 20 months [36].”
The Genomic Landscapes of Human Breast and Colorectal Cancers
Wood, L. D., Parsons, D. W., Jones, S., Lin, J., Sjöblom, T., Leary, R. J., Shen, D., Boca, S. M., Barber, T., Ptak, J., et al. (2007) · Science · doi:10.1126/science.1145720 · Cited by 2,833 · cited 1×
“[3].”
The PI3K Pathway in Human Disease
Fruman, D. A., Chiu, H., Hopkins, B. D., Bagrodia, S., Cantley, L. C., & Abraham, R. T. (2017) · Cell · doi:10.1016/j.cell.2017.07.029 · Cited by 2,749 · cited 1×
“In the GTP-bound state, KRAS activates downstream effectors, initiating multiple signaling pathways, including the RAF kinase family and phosphatidylinositol 3-kinase (PI3K), which promote various cellular functions [8,9] (Figure 1).”
Whole genomes redefine the mutational landscape of pancreatic cancer
Initiative, A. P. C. G., Waddell, N., Pajic, M., Patch, A.-M., Chang, D. K., Kassahn, K. S., Bailey, P., Johns, A. L., Miller, D., Nones, K., et al. (2015) · Nature · doi:10.1038/nature14169 · Cited by 2,642 · cited 1×
“For example, G12V is frequently identified in pancreatic ductal adenocarcinomas and is associated with aggressive disease biology [16,21].”
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557 · cited 1×
“While G12C and G12D have garnered significant attention due to the development of novel small molecule inhibitors [19,20], other substitutions remain relatively underexplored in terms of direct targeted therapies.”
The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity
Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277 · cited 1×
“While G12C and G12D have garnered significant attention due to the development of novel small molecule inhibitors [19,20], other substitutions remain relatively underexplored in terms of direct targeted therapies.”
Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer
Douillard, J.-Y., Oliner, K. S., Siena, S., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305275 · Cited by 2,263 · cited 1×
“The most frequently detected mutations in codons 12 and 13—namely G12V (incidence: 20–25%), G12S (5–7%), G12R (3–5%), G12A (3–5%), and G13D (15–20%)—are also clinically relevant, with their prevalence varying by tumor type [16–18].”
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997 · cited 3×
“For example, G12V is frequently identified in pancreatic ductal adenocarcinomas and is associated with aggressive disease biology [16,21].”
COSMIC: somatic cancer genetics at high-resolution
Forbes, S. A., Beare, D., Boutselakis, H., Bamford, S., Bindal, N., Tate, J., Cole, C. G., Ward, S., Dawson, E., Ponting, L., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw1121 · Cited by 1,922 · cited 1×
“Moreover, G12S and G12A occur in both colorectal and lung cancers at lower but still significant frequencies [16,17].”
Cited by
Advances in Cancer Treatment Through Nanotheranostics and Emerging Therapies
Akpe, V., & Cock, I. E. (2025) · Journal of Nanotheranostics · doi:10.3390/jnt6040029 · Cited by 30
“It has been demonstrated that IL-10 can induce upregulation of TIM-3 on human T cells, leading to functional exhaustion and suppression of antitumor immunity [275].”
Kyrochristou, I. D., Lianos, G. D., Kyrochristou, G. D., Anagnostopoulos, G. C., Bali, C. D., Boussios, S., Mitsis, M. C., Schizas, D., & Vlachos, K. (2025) · Biomedicines · doi:10.3390/biomedicines13082038 · Cited by 18
“KRAS mutations are one of the most studied groups of molecular signatures and targets in CRC patients, as they are extremely often (42% of CRC patients have KRAS mutations) [45].”
Cancer Metastasis: Therapeutic Challenges and Opportunities
Garemilla, S. S. S., Kadambala, M. C., Gampa, S. C., Chinthala, S., & Garimella, S. V. (2025) · Medical Oncology · doi:10.1007/s12032-025-03072-x · Cited by 15
“For example, in colorectal cancer liver metastases, regionally heterogeneous KRAS mutations are linked to significantly poorer survival (18 vs 37 months), reflecting how divergent subclones adapt to different organ microenvironment [44].”
Emerging nano-immunotherapeutic strategies achieve metastatic colorectal cancer precision therapy
Jiang, S., Zhang, Z., Mao, Y., Xia, X., Luo, J., Zhang, Y., & Yuan, Y. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03933-7 · Cited by 13
“…metastasectomy to consolidate systemic antitumor immunity (NCT04486378) [54]. mRNA-5671/V941, in contrast, delivers mRNA encoding shared KRAS mutations (G12C, G12D, G12V, G13D) and is being evaluated with pembrolizumab in KRAS-mutant colorectal cancer and other solid tumors (NCT03948763) [55].”
Tang, N., Sun, W., Zhang, J., Ma, X., & Wang, Y. (2025) · Food and Chemical Toxicology · doi:10.1016/j.fct.2025.115543 · Cited by 10
Metadata
- Authors
- Takeda, M., Yoshida, S., Inoue, T., Sekido, Y., Hata, T., Hamabe, A., Ogino, T., Miyoshi, N., Uemura, M., Yamamoto, H., Doki, Y., & Eguchi, H.
- Affiliations
- The University of Osaka (JP)
- Corresponding author
- Takeda, Mitsunobu
- ORCID
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2025-01-27
- Volume
- 17
- Issue
- 3
- Pages
- 428
- ISSN
- 2072-6694 (ISSN-L)
- PMC
- PMC11816235
- OpenAlex
- W4406867792
- Semantic Scholar
- 2803fdbec8d915a47df49692d27cd1e6edb65e91
- Cited by
- 82
- References
- 84
- Citations by year
- 2026: 52 · 2025: 30
- FWCI
- 9.59
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancers (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Japan Society for the Promotion of Science (23K08128)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- KRAS mutation, colorectal cancer, ERK signaling, PI3K/Akt signaling, tumor microenvironment, cancer stem cells, macropinocytosis, cell competition, anti-EGFR therapy resistance, KRAS inhibitors, KRAS G12C inhibitors, sotorasib, adagrasib, KRAS G12D, combination therapy, cancer vaccines, nucleic acid therapeutics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives. https://app.cochat.ai/papers/10.3390/cancers17030428
- The paper
- Takeda, M., Yoshida, S., Inoue, T., Sekido, Y., Hata, T., Hamabe, A., Ogino, T., Miyoshi, N., Uemura, M., Yamamoto, H., Doki, Y., & Eguchi, H. (2025). The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives. Cancers. https://doi.org/10.3390/cancers17030428
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.